Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver dise...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2021-05-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1611 |
| _version_ | 1811173891004956672 |
|---|---|
| author | Enxiang Zhang Yang Zhao Hongbo Hu |
| author_facet | Enxiang Zhang Yang Zhao Hongbo Hu |
| author_sort | Enxiang Zhang |
| collection | DOAJ |
| description | Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2‐mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction. During the progression of NAFLD, there are some hallmark complications, including lipid metabolism disorders, inflammation induction, and hepatocyte death. Herein, we review several SGLT2 inhibitors that are capable of protecting individuals with NAFLD from severe complications by inhibiting de novo lipogenesis, oxidative responses, inflammation induction, and hepatocyte death. |
| first_indexed | 2024-04-10T17:55:24Z |
| format | Article |
| id | doaj.art-b3a33dfccae04ee9b6cd97426ebd984e |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-04-10T17:55:24Z |
| publishDate | 2021-05-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-b3a33dfccae04ee9b6cd97426ebd984e2023-02-02T18:55:15ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2021-05-015573674810.1002/hep4.1611Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes MellitusEnxiang Zhang0Yang Zhao1Hongbo Hu2Key Laboratory of Growth Regulation and Transformation Research of Zhejiang Province School of Life Sciences Westlake Institute for Advanced StudyWestlake University Shilongshan Hangzhou ChinaDepartment of Cardiology Zhejiang Provincial People’s Hospital Hangzhou ChinaBeijing Advanced Innovation Center for Food Nutrition and Human Health College of Food Science and Nutritional Engineering China Agricultural University Beijing ChinaSodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2‐mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction. During the progression of NAFLD, there are some hallmark complications, including lipid metabolism disorders, inflammation induction, and hepatocyte death. Herein, we review several SGLT2 inhibitors that are capable of protecting individuals with NAFLD from severe complications by inhibiting de novo lipogenesis, oxidative responses, inflammation induction, and hepatocyte death.https://doi.org/10.1002/hep4.1611 |
| spellingShingle | Enxiang Zhang Yang Zhao Hongbo Hu Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus Hepatology Communications |
| title | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus |
| title_full | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus |
| title_fullStr | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus |
| title_full_unstemmed | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus |
| title_short | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus |
| title_sort | impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus |
| url | https://doi.org/10.1002/hep4.1611 |
| work_keys_str_mv | AT enxiangzhang impactofsodiumglucosecotransporter2inhibitorsonnonalcoholicfattyliverdiseasecomplicatedbydiabetesmellitus AT yangzhao impactofsodiumglucosecotransporter2inhibitorsonnonalcoholicfattyliverdiseasecomplicatedbydiabetesmellitus AT hongbohu impactofsodiumglucosecotransporter2inhibitorsonnonalcoholicfattyliverdiseasecomplicatedbydiabetesmellitus |